Characterization of Thyroid Hormone Receptor (THR) Agonists for the Treatment of Non-Alcoholic Steatohepatitis (NASH) by Quantification of In Vitro & In Vivo Gene Transcription

Time: 11:30 am
day: Day 2 Stream 1 AM


• Hearing how Aligos has implemented a strategy to rank the efficacy of THR agonists by quantifying changes in the transcription of genes that lead to metabolic alterations, an effect that is directly downstream of THR binding and activation.
• Comparing the ability of THR-agonism-based NASH treatment candidates to modulate the expression of genes related to cholesterol and fatty acid biosynthesis and metabolism in vitro using Huh-7 cells and primary human hepatocytes.
• Understanding how our observations in vitro were confirmed in a HFD-fed rodent model, where treatment with THR agonists resulted in significant, dose-dependent increases in the liver gene expression that correlate well to a reduction in lipid levels.